Product Information: Nitnib 12.5mg Capsules
1. Indications & Usage
Nitnib 12.5mg Capsules are indicated primarily under strict professional medical, clinical research, and specialist oncology supervision for:
Advanced Renal Cell Carcinoma (RCC): Prescribed for the systemic treatment of advanced or metastatic renal cell carcinoma.
Gastrointestinal Stromal Tumor (GIST): Indicated for the treatment of gastrointestinal stromal tumors after disease progression on or intolerance to imatinib mesylate.
Pancreatic Neuroendocrine Tumors (pNET): Administered for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable locally advanced or metastatic disease.
2. Mechanism of Action: Multi-Kinase & Angiogenesis Inhibition
Sunitinib stops oncogenic cellular duplication and vascular blood supply tracking through precise target receptor blockade:
Simultaneous RTK Inhibition: Nitnib targets and binds to multiple receptor tyrosine kinases, specifically blocking vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3) and platelet-derived growth factor receptors (PDGFR-Ξ±, PDGFR-Ξ²).
Angiogenesis Arrest: By shutting down downstream VEGFR signaling pathways within endothelial cells, it starves the tumor matrix of essential oxygen and blood capillary growth.
Tumor Microenvironment Disruption: It targets KIT (CD117), FLT3, and RET signaling lines, permanently interrupting intracellular proliferation cascades and inducing tumor cell apoptosis.
3. Storage, Stability & Commercial Packaging Specifications
Temperature Maintenance: Store in a dry, cool environment below 30Β°C.
Protect shipments from prolonged thermal spikes, moisture vapor transmission, and direct ambient ultraviolet sunlight. Commercial Integrity: Packed in standard high-density polyethylene (HDPE) bottles containing specialized desiccant inserts or heavy-duty foil blister setups designed to withstand long-range transit variables.
Safety Protocol: Keep strictly out of the sight and reach of children.
4. Safety Profile, Side Effects, and Clinical Monitoring
Because Nitnib is a highly potent antineoplastic agent, ongoing specialist clinical monitoring is mandatory to protect patient safety.
Common Manifestations: Fatigue, diarrhea, nausea, stomatitis, dyspepsia, hypertension, and hand-foot syndrome (palmar-plantar erythrodysesthesia).
Cardiovascular & Hematological Monitoring: Regular evaluation of left ventricular ejection fraction (LVEF) and blood pressure metrics is strongly advised.
Routine complete blood counts (CBC) are required due to potential myelosuppression (neutropenia, thrombocytopenia). Hepatic Supervision: Periodic liver function profiles (ALT/AST/Bilirubin) must be carried out to safeguard against drug-induced hepatotoxicity.
5. Regulatory and Compliance Documentation
ERNEST IMPEX ensures that every trade lane shipment of Nitnib 12.5mg complies with strict international customs and medical export expectations by providing:
Comprehensive Commercial Invoice & Itemized Packing Lists
Validated Certificates of Analysis (CoA) from approved laboratories
Legalized Export Documentation (IEC & Custom shipping clearance data)
Secure, temperature-shielded freight layout for air or cargo routing
π‘ Why Choose ERNEST IMPEX?
Direct sourcing channels from verified manufacturing infrastructure in India
Scale-ready capacity for hospital groups, clinical distributors, and regional wholesalers
Precision documentation routing for transparent customs tracking
Dedicated global trade desks providing end-to-end support
PRESCRIPTION MEDICINE: YES
Nitnib 12.5mg Capsules must be supplied and administered strictly under the authority of a registered professional. The clinical and pharmacological data listed here serves strictly as a commercial guide for international bulk procurement, regulatory compliance matching, and wholesale trade awareness.
π Contact Ernest Impex β Pharmaceutical Exporter from India
[GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.]
